ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Savara Inc

Savara Inc (SVRA)

3.25
0.01
(0.31%)
Closed December 23 4:00PM
3.25
0.005
(0.15%)
After Hours: 7:51PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.000.002.650.000.000.000.00 %00-
2.000.951.702.501.3250.000.00 %01-
3.000.150.700.390.4250.000.00 %01-
4.000.050.150.100.100.000.00 %0195-
5.000.150.750.150.450.000.00 %01-
6.000.000.750.000.000.000.00 %00-
7.001.000.350.050.675-0.95-95.00 %2112/23/2024

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.000.500.750.500.6250.000.00 %01-
2.000.000.250.000.000.000.00 %00-
3.000.000.500.000.000.000.00 %00-
4.000.503.200.001.850.000.00 %00-
5.001.554.200.002.8750.000.00 %00-
6.002.453.300.002.8750.000.00 %00-
7.002.904.300.003.600.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DRCTDirect Digital Holdings Inc
$ 5.25
(854.55%)
68.49M
CHEKCheck Cap Ltd
$ 2.24
(279.66%)
40.03M
SLGLSol Gel Technologies Ltd
$ 1.57
(265.97%)
18.2M
RELIReliance Global Group Inc
$ 3.08
(156.67%)
104.84M
TRAWTraws Pharma Inc
$ 12.50
(149.00%)
27.89M
AILEiLearningEngines Inc
$ 0.199
(-77.51%)
29.69M
MGOLMGO Global Inc
$ 0.4765
(-49.84%)
14.06M
YHCLQR House Inc
$ 1.11
(-36.57%)
1.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.4014
(-34.37%)
192.19M
ADGMAdagio Medical Holdings Inc
$ 1.095
(-33.64%)
4.83M
EDBLEdible Garden AG Inc
$ 0.3669
(54.35%)
410.01M
RGTIRigetti Computing Inc
$ 10.945
(16.81%)
229.36M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.4014
(-34.37%)
195.36M
NVDANVIDIA Corporation
$ 139.67
(3.69%)
175.95M
RIMEAlgorhythm Holdings Inc
$ 0.0925
(21.07%)
155.99M

SVRA Discussion

View Posts
Monksdream Monksdream 8 months ago
SVRA under $5
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
SVRA under $5
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 year ago
SVRE fresh nazy with volume
πŸ‘οΈ0
glenn1919 glenn1919 1 year ago
SVRA.......................https://stockcharts.com/h-sc/ui?s=SVRAp=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
SVRA new 52 week high
πŸ‘οΈ0
glenn1919 glenn1919 2 years ago
SVRA................................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 2 years ago
SVRA...................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 2 years ago
SVRA.................................https://stockcharts.com/h-sc/ui?s=SVRAp=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 2 years ago
SVRA.................................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
AKAPAK AKAPAK 2 years ago
Impala must be doing better ... hod $2.82 been making nice moves during last few days!
πŸ‘οΈ0
AKAPAK AKAPAK 2 years ago
Wake up call to the board $2.47
πŸ‘οΈ0
Mrfairfield Mrfairfield 4 years ago
Finally done dumping on the new financials. Looks like consolidation and ??????
πŸ‘οΈ0
20stockman20 20stockman20 4 years ago
Looking for comments,
What some see as a dump, others see as an opportunity.
What say you?
πŸ‘οΈ0
Roadtojourney Roadtojourney 4 years ago
Wow looks like dump is still on imo
πŸ‘οΈ0
20stockman20 20stockman20 4 years ago
Check out what BARCHART has to say about SVRA

Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.
πŸ‘οΈ0
20stockman20 20stockman20 4 years ago
jumped in, looks good to me
πŸ‘οΈ0
lecorb lecorb 4 years ago
Savara Inc Stock may give you a sharp bounce - svra stock



Last Ratings
3/16/2021 Piper Sandler Initiated Coverage Overweight $7.00 High
3/15/2021 Oppenheimer Initiated Coverage Outperform $4.00 High
πŸ‘οΈ0
Klinsmann Klinsmann 4 years ago
Not really, had 120 million volume yesterday
But volume is far about average and chart is building!
Many big institutional investors, plus company insiders holding big positions.
πŸ‘οΈ0
ronjon41 ronjon41 4 years ago
The volume today should say it all, surpassed yesterdays volume in the first 30 minutes.
πŸ‘οΈ0
maximumgriff maximumgriff 4 years ago
Looks like they still at it
πŸ‘οΈ0
Jess070283 Jess070283 4 years ago
This is one you need for long term. Just warming up. My price target is $5-10!
πŸ‘οΈ0
trendzone trendzone 4 years ago
Corrupt MM's manipulation brought it down from the highs yesterday's.
πŸ‘οΈ0
Klinsmann Klinsmann 4 years ago
Jep, 100% agree. It traded volume of a whole year on one day while insiders have been buying. For reason imo
πŸ‘οΈ0
maximumgriff maximumgriff 4 years ago
Closed a massive 130 mill Offering! Check out the AH filings! This will run soon!!
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $SVRA Video Chart 03-16-2021 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
DMOST DMOST 5 years ago
In the money Jan. 6: Drug, burger makers report multimillion-dollar fundings

..................................

β€’ Savara Inc. has raised about $26.8 million as it develops drugs to treat rare lung diseases. The Austin-based pharmaceutical company announced Dec. 20 it intended to sell more than 9.5 million shares of common stock and pre-funded warrants to buy more than 5.7 million shares in a private placement with "institutional investors," which would generate the $26.8 million, although Savara (Nasdaq: SVRA) still needs to deduct placement agent fees and other offering expenses. The company filed securities paperwork Jan. 2 indicating it had raised the $26.8 million from 18 investors. Savara said Dec. 20 it has also agreed to sell warrants that could allow investors to buy more than 32.5 million additional shares of common stock. The warrants can be exercised by investors two years after the close of this private placement or 30 days after Savara achieves a certain clinical milestone, whichever is earlier. That sale could raise gross proceeds of $48.2 million, according to the company, before deducting expenses and fees. Bain Capital Life Sciences led the placement and Ricky Sun of Bain Capital has joined Savara's board of directors. Investors in the private placement included EcoR1 Capital LLC and Logos Capital. Founded in 2008, Savara is led by CEO Rob Neville and develops drugs for orphan lung diseases such as autoimmune pulmonary alveolar proteinosis and nontuberculous mycobacteria.
https://www.bizjournals.com/austin/news/2020/01/06/in-the-money-jan-6-drug-burger-makers-report.html?ana=yahoo&yptr=yahoo


GO SVRA

"PEACE"
πŸ‘οΈ0
DMOST DMOST 5 years ago
DMOST....."In Like Flint", look towards a huge pay day down the road, in a relatively short time frame.

Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?

Investors in Savara Inc. SVRA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 $5.00 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for Savara shares, but what is the fundamental picture for the company? Currently, Savara is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Top 23% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimate for the current quarter, while none have dropped their estimates. The net effect has narrowed our Zacks Consensus Estimate for the current quarter from a loss of 52 cents per share to a loss of 49 cents in that period.

Given the way analysts feel about Savara right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
https://finance.yahoo.com/news/options-traders-betting-big-move-143002217.html

GO SVRA

"PEACE"
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $SVRA Video Chart 01-02-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $SVRA Video Chart 12-31-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
chrispy2468 chrispy2468 5 years ago
So. We buying calls or puts? 5 strikes.
πŸ‘οΈ0
boston127 boston127 5 years ago
We never lose taking profits.

I'm waiting for the right moment to get back in. It will probably not be today. I also have 2 other stocks on my radar that I have been following, and investing in, for awhile. US*W*S and AU**XX*F
πŸ‘οΈ0
BoilerRoom BoilerRoom 5 years ago
What’s the offering price?
πŸ‘οΈ0
alchemytrader alchemytrader 5 years ago
You were alerted at 2.30 multiple times bud.
πŸ‘οΈ0
BoilerRoom BoilerRoom 5 years ago
Looks like run is over here. Needs consolidate
πŸ‘οΈ0
Hercules1 Hercules1 5 years ago
I did the same damn thing:


I sold too soon for a decent profit but should have held on for a day or two.



πŸ‘οΈ0
williamssc williamssc 5 years ago
$$Nice move up today. Congrats.
5.7400 +0.83 (16.90%)
After hours: 7:59PM EST
πŸ‘οΈ0
boston127 boston127 5 years ago
I got it - sold too soon.

Was so glad to make a buck, sold way too soon. I will get back in tomorrow after seeing the after hours action and the Bain Capital's 9.9% stake.
πŸ‘οΈ0
Biobonic Biobonic 5 years ago
Their latest presentation is worth a listen Savara

An understanding is that the Impala trial would have passed if not for a small group of 4 in the placebo group who use oxygen. Their use of oxygen is necessary, and they were allowed to use oxygen during the actual 6 minute walk. The rate of oxygen they used during the walk increased due to the exertion necessary, this raised the placebo groups score.

Would appreciate any feedback...
πŸ‘οΈ0
north40000 north40000 5 years ago
http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81434794/current-report-filing-8-k

http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81438175/statement-of-beneficial-ownership-sc-13d

http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81434542/savara-granted-breakthrough-therapy-designation-fo

"....The Molgradex Breakthrough Therapy designation is based on data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex for the treatment of aPAP. Data from the study was recently presented in an oral session at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain.

β€œWe are pleased that the FDA recognized Molgradex as a breakthrough therapy for the treatment of aPAP, a debilitating rare lung disease with no approved pharmacologic treatment options,” said Rob Neville, Chief Executive Officer, Savara. β€œWe believe this designation reflects the significance of Molgradex as an investigational product that, based on the IMPALA study, has been demonstrated to improve patient outcomes. Breakthrough designation is designed to provide increased collaboration and more frequent dialogue with the FDA and is an important milestone as we work to determine the best path forward for this product.”

About Savara

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)....."

πŸ‘οΈ0
Rocketred Rocketred 5 years ago
over 6 buks now
πŸ‘οΈ0
davidsson10 davidsson10 5 years ago
So far this evening, the $3.50 area is proving to have been a prescient reload point for Round Two. Another double waiting in the wings? We'll know soon enough.....
πŸ‘οΈ0
Biobonic Biobonic 5 years ago
Go to the presentations on SVRA website
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $SVRA Video Chart 12-30-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
steez steez 5 years ago
Wow
πŸ‘οΈ0
Hercules1 Hercules1 5 years ago
I think $5 break is coming right up.
πŸ‘οΈ0
Hercules1 Hercules1 5 years ago
it is going to make a run to $5.



could open at $6 tomorrow.





πŸ‘οΈ0
Rocketred Rocketred 5 years ago
WOW smoking hot on FDA approval
πŸ‘οΈ0
Hercules1 Hercules1 5 years ago
here we go people:


$4 break is coming right up.



πŸ‘οΈ0
Hercules1 Hercules1 5 years ago
Looks like there will be a short squeeze here.

This is going up bigly.
πŸ‘οΈ0
Hercules1 Hercules1 5 years ago
This is fixing to make another explosive jump.

Can easily close at $4.50 to $5
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock